Current cancer drug targets最新文献

{"title":"The Role of Nrf2 in Glioma: Therapeutic Targeting Strategies.","authors":"Mohammad Sadra Harifi-Mood, Effat Alemzadeh, Danyal Barati, Amir Hossein Dehghani, Fatemeh Zahra Siroosi, Michael Aschner, Fariborz Samini, Saeed Samarghandian, Tahereh Farkhondeh","doi":"10.2174/0115680096331620250119111525","DOIUrl":"https://doi.org/10.2174/0115680096331620250119111525","url":null,"abstract":"<p><p>Cancer is one of the most challenging diseases to cure due to its complexity. Gli-oma, as a neuroepithelial cancer of the glial cells, is one of the rarest malignancies which has a low survival rate. The exact risk factors of glioma are still not clear, but allergy, ionizing radiation, and hereditary factors are reported to be associated with glioma. Nrf2 as an antiox-idant regulator has been reported to be highly expressed in malignances tissues like glioma. Nrf2 regulates the expression of various antioxidant and cytoprotective genes. In gliomas, Nrf2 activation helps tumor cells combat oxidative stress by enhancing the production of de-toxifying enzymes (e.g., glutathione peroxidase, NADPH quinone oxidoreductase). This al-lows glioma cells to survive and proliferate in toxic tumor microenvironments rich in reactive oxygen species (ROS). Although the role of Nrf2 in the apoptosis of cancerous glial cells is not clear yet, it has been shown that Nrf2 inhibition via different methods can increase the efficiency of the chemo-therapy agents to treat glioma. Elevated Nrf2 activity has been linked to drug resistance in gliomas. The activation of Nrf2 increases the expression of multidrug resistance-associated proteins (MRPs) and other detoxifying enzymes, which limit the effectiveness of chemother-apeutic agents like temozolomide (TMZ). Nrf2 inhibitors can suppress the signaling pathway of Nrf2 and decrease the expression of detoxifying enzymes like SOD, CAT, GPX, and GCL, which can increase the efficiency of chemotherapy agents. Using drugs that inhibit the Nrf2 expression in combination with classical chemotherapy agents can be a promising procedure to decrease chemoresistance and be effective in increasing the survival rate of patients with glioma. In this study, we focused on the association of glioma and Nrf2 expression and its targeting as a new therapeutic approach in glioma treatment.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Groundbreaking mRNA Lung Cancer Vaccine Trials: A New Dawn in Cancer Treatment.","authors":"Md Sadique Hussain, Ayesha Sultana, Ajay Singh Bisht, Gaurav Gupta","doi":"10.2174/0115680096360059250131075456","DOIUrl":"https://doi.org/10.2174/0115680096360059250131075456","url":null,"abstract":"<p><p>The advent of mRNA vaccines has heralded a transformative era in oncology, exemplified by the BNT116 mRNA lung cancer vaccine. Leveraging the same ground-breaking technology as COVID-19 vaccines, BNT116 delivers tumor-specific genetic in-structions to the immune system, targeting non-small cell lung cancer (NSCLC), the most prevalent lung cancer subtype. This approach contrasts with conventional therapies that lack precision and often damage healthy tissues. By encoding tumor antigens, BNT116 educates cytotoxic T cells to recognize and eradicate malignant cells, aligning with the principles of precision medicine. Early-phase clinical trials (e.g., NCT05142189) have demonstrated a favorable safety profile and promising antitumor activity, with ongoing re-search exploring its use in combination therapies, such as checkpoint inhibitors. Despite logistical challenges, such as mRNA instability and cold chain requirements, advances in lipid nanoparticle delivery systems are enhancing vaccine stability and efficacy. The adaptability of mRNA technology positions it as a cornerstone for personalized oncology, with potential applications extending to other cancers. Success in the BNT116 trials could redefine NSCLC treatment paradigms, offering a targeted, less cytotoxic alternative. This innovation can not only improve therapeutic outcomes, but also pave the way for preven-tive cancer vaccines, signaling a new dawn in cancer treatment.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Potential of Terpenes in Lung Cancer: Modulation of 4-Oxo-Retinoic Acid, TNF-α, NF-κB, and HDAC2 Pathways.","authors":"Janmejay Pant, Payal Mittal, Lovedeep Singh","doi":"10.2174/0115680096353438250130070422","DOIUrl":"https://doi.org/10.2174/0115680096353438250130070422","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) includes various epithelial malignancies, such as squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Despite ad-vancements in surgical resection, chemoradiotherapy, and multimodal therapies, NSCLC prognosis remains challenging due to its complex molecular landscape, drug resistance, and high treatment costs. Recent research highlights the potential of natural compounds, particularly terpenes and terpenoids, derived from essential oils (EOs), to enhance NSCLC treatment. These compounds exhibit anticancer properties and modulate key pathways like the 4-oxo-retinoic acid pathway, TNF-α signaling, NF-κB activation, and histone deacety-lases (HDACs). Retinoids, a subclass of terpenes, show both chemopreventive and thera-peutic benefits, especially when combined with other agents, though challenges in dosing and delivery methods limit their clinical application. Terpenes may also synergize with emerging therapies, such as antiangiogenic treatments and immunotherapy, to improve outcomes. Biomarkers, including genomic, epigenomic, and proteomic markers, play a critical role in predicting responses to terpene-based treatments, supporting personalized medicine. The integration of terpenes into existing regimens, in combination with conven-tional therapies, holds promise in overcoming clinical challenges, improving patient out-comes, and advancing natural compound use in modern oncology. Future research should focus on optimizing terpene therapies and addressing clinical hurdles.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"7-Dehydrocholesterol Reductase Activates the Hedgehog Pathway by Regulating Cholesterol to Promote the Development of Triple-Negative Breast Cancer.","authors":"Shuang Qiu, Yu Sun, Yuanyuan Liu, Jinyu Yang, Xin Chen, Di Wu, Li Li, Jianwei Sun","doi":"10.2174/0115680096363566250119155918","DOIUrl":"10.2174/0115680096363566250119155918","url":null,"abstract":"<p><strong>Background: </strong>Cholesterol has been shown to be a potential risk factor for the occurrence and progression of breast cancer. This study aimed to investigate the regulation of DHCR7 in cholesterol synthesis and its role in Hedgehog (Hh) signaling pathway activation, as well as its impact on the progression of triple-negative breast cancer (TNBC).</p><p><strong>Methods: </strong>We analyzed the gene expression data from the GSE76275 data set by bioinformatics analysis to determine the expression of cholesterol-related genes in triple-negative breast cancer. In the triple-negative breast cancer cell lines, including BT-549 and MDA-MB-231, RNA interference gene knockout was used to evaluate the functional impact of DHCR7. In addition, the SMO mutant (SMOV329F) with anti-cholesterol binding inhibition was introduced to determine its interaction with the pathway changes mediated by DHCR7. Cell proliferation, migration, and signaling pathway activation were assessed through Western blotting, CCK-8 assay, transwell migration assay, and qPCR.</p><p><strong>Results: </strong>DHCR7 expression was significantly elevated in TNBC tissues and cell lines, enhancing the Hh pathway activity through cholesterol modulation. Knocking down DHCR7 and the SMOV329F mutation both reduced the expression of Hedgehog-related proteins and inhibited cell proliferation and migration abilities. However, the SMOV329F mutation re-versed the inhibitory effect of knocking down DHCR7 on TNBC cells.</p><p><strong>Conclusion: </strong>DHCR7 activates the Hedgehog pathway by regulating cholesterol to promote the development of TNBC. These findings provide insights into the regulatory roles of DHCR7 in cholesterol-related pathways and Hh signaling in TNBC cells, offering potential therapeutic targets for TNBC treatment.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of DNA Replication factor MCM2 by Cancer.","authors":"Yuwei Yuan, Tian Zeng, Anbo Gao, Yang Guan, Qun-Feng Zhang, Yukun Li, Hui Tan, Juan Zou","doi":"10.2174/0115680096349638250117101910","DOIUrl":"https://doi.org/10.2174/0115680096349638250117101910","url":null,"abstract":"<p><p>MCM2 belongs to the microchromosome maintenance [MCM] family and plays an essential role in initiating DNA replication as well as maintaining normal cellular cycle functions. Recent research indicates that there is the abnormal expression of MCM2 in various cancers, such as breast, cervical, ovarian, lung, hepatocellular carcinoma, nephroblastoma, prostate, and pancreatic cancers, where it shows a strong link to tumorigenesis, growth, invasion, migration, and adverse prognosis. Thus, MCM2 could serve as a significant biomarker for the early identification, diagnosis, and prognostic evaluation of multiple cancers. In addition, targeting MCM2 expression may open new possibilities for a full range of cancer treatments. In this paper, the protein structure, physiological function, and carcinogenic mechanism of MCM2 were reviewed.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Cutaneous Carcinoma Therapy Through Integrated Use of Immunotherapy and Nanotechnology.","authors":"Tenzin Tsering Dongsar, Kartik Bajaj, Tenzin Sonam Dongsar, Ahbab Ali, Nazeer Hasan, Farhan Jalees Ahmad","doi":"10.2174/0115680096349248250113093025","DOIUrl":"https://doi.org/10.2174/0115680096349248250113093025","url":null,"abstract":"<p><p>Skin cancer is one of the most lethal cancers today, posing significant challenges to public health and potentially impacting global health and economic stability. Due to its high rate of incidence, innovative and effective treatments are crucial. Among these, immunothera-peutic approaches have emerged as transformative, offering new hope by harnessing the body's immune system to target and eliminate cancerous cells. Immunotherapy has changed the treatment landscape for skin cancer, providing options such as checkpoint inhibitors and adoptive cell transfer therapies that specifically enhance immune activity against tumors. De-spite these advancements, the broader adoption of immunotherapeutic modalities is challeng-ing due to concerns about their toxicity and variable efficacy. The side effects, such as im-mune-related adverse events, can be severe and sometimes limit their use. In response to these challenges, nanotechnology in cancer treatment has gained significant attention. Nanotechnol-ogy-based approaches show promise in improving the delivery and effectiveness of cancer therapies, particularly for skin cancer immunotherapy. Nanoparticles can deliver therapeutic agents directly to tumors, minimizing systemic toxicity and enhancing treatment precision. These strategies also boost the immune system's ability to target cancer cells while overcom-ing the limitations of current immunotherapies. This review explores various anticancer thera-peutic approaches for managing skin cancer, focusing on immunotherapy and its challenges. It highlights how integrating nanotechnology with cancer immunotherapy offers a promising av-enue for enhancing treatment efficacy and safety. The review also provides an overview of re-cent advancements in skin cancer treatment, showcasing how these innovative strategies are paving the way for more effective and less toxic therapeutic options in combating one of the deadliest cancers.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Review on Anticancer Potential of <i>Pulicaria</i> Plants and their Derivatives.","authors":"Tahere Barabadi, Hossein Rahimi, Seyed Mahdi Mohamadi-Zarch, Seyyed Majid Bagheri","doi":"10.2174/0115680096358261250115114608","DOIUrl":"https://doi.org/10.2174/0115680096358261250115114608","url":null,"abstract":"<p><p>The genus Pulicaria, belonging to the Asteraceae family, includes 100 species distributed from Europe to North Africa and Asia, especially around the Mediterranean. A number of extracts and compounds of this genus have been found to have anticancer effects on various cancer cell lines. Google, PubMed, Web of Science and Scopus databases were searched for articles related to Pulicaria or its isolated compounds. The search was conduct-ed using various keywords, including \"Pulicaria and anticancer activity\". After the review, the relevant articles were summarized and included in the review article. Fortunately, the re-sults of this review showed that relatively comprehensive studies have been conducted in this field, and the presence of various compounds in these plants can be used in cancer re-search. The results of our review showed that Pulicaria vulgaris has the strongest effect and Pulicaria dysenterica has the weakest effect on cancer cells. Future studies should focus on finding purer compounds and investigating the anticancer effects of these compounds. These herbal compounds can also be used alongside standard drugs to treat cancer, especially to reduce the effect of drug resistance.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of the Progress in the Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma.","authors":"Dongying Liao, Jiayu Liu, Qingpeng Jin, Xiaoqun Wang, Na Wang, Yingjie Jia, Fanming Kong","doi":"10.2174/0115680096341070250109074108","DOIUrl":"https://doi.org/10.2174/0115680096341070250109074108","url":null,"abstract":"<p><p>Pulmonary sarcomatoid carcinoma（PSC）is a rare pathological type of non-small cell lung cancer that combines the characteristics of epithelial and mesenchymal tu-mors and is an extremely malignant and highly heterogeneous malignant tumor. PSC is dif-ficult to diagnose and has a poor sensitivity to radiotherapy. In recent years, with the effica-cy breakthroughs of molecularly targeted drugs and immune checkpoint inhibitors in tumor therapy, the treatment of PSC is gradually exploring precise targeted therapy and immuno-therapy. In this article, we will provide a comprehensive review of the clinical features, di-agnostic points, and progress in the clinical therapeutic research of PSC. We hope to provide guidance and help with clinical treatment and scientific research.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced Efficacy of Radiation Therapy against Glioblastoma by Attenuated Salmonella Carrying Co-Expression Plasmids with siRNA-PD-L1 and Endostatin.","authors":"Yinghua Ji, Jiaming Guo, Hanyu Jiang, Weiwei Ren, Jiaxin Geng, Mengyu Lei, Jiahang Li, Peiyuan Dang, Yu Wang, Xin Chen, Tiesuo Zhao, Chengbiao Lu, Huijie Jia, Jin Yang","doi":"10.2174/0115680096344636250101074632","DOIUrl":"https://doi.org/10.2174/0115680096344636250101074632","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM), a common type of brain tumor, is currently treatable through radiation therapy. However, there is room for improvement in the effec-tiveness of treatment. Radiation can lead to an increase in the expression of PD-L1 and VEGF, which might reduce the responsiveness of the tumor to the therapy. This situation underlines the necessity for innovative treatment strategies.</p><p><strong>Objectives: </strong>In this study, we investigated the potential of attenuated Salmonella carrying the co-expressing plasmid siPD-L1-Endo to effectively inhibit PD-L1 and VEGF expres-sion, thereby enhancing the anti-tumor effects of radiation therapy in GBM-bearing mice.</p><p><strong>Methods: </strong>The regulatory mechanisms responsible for the treatment effect were detected by Flow cytometry, Immunohistochemistry, TUNEL, Immunofluorescence, H&E staining, and Western blot assays.</p><p><strong>Results: </strong>Upon administration of attenuated Salmonella carrying siRNA-PD-L1 and co-expressing endostatin plasmids, the results exhibited significant suppression of tumor growth and tumor cell proliferation, as well as a concurrent decrease in PD-L1 and VEGF expression in tumor tissues. Moreover, the treatment led to reduced expression levels of tumor-related proteins p-Stat3, MMP2, Cyclin D1, and PCNA, an increase in the expres-sion of the apoptosis-related protein cleaved-caspase3, facilitated infiltration of CD4+ and CD8+ T cells within tumor tissues, and an elevation of the ratios of CD4+, CD8+ T cells, and NK cells in the spleen of tumor-bearing mice.</p><p><strong>Conclusion: </strong>These findings highlight the ability of attenuated Salmonella carrying siR-NA-PD-L1 and co-expressing endostatin plasmids to effectively modulate PD-L1 and VEGF expression, thus strengthening the anti-tumor immune response in GBM-bearing mice subjected to radiation therapy. This combination therapy approach holds promise as a potential avenue for improving the efficacy of radiation therapy in the treatment of glio-blastoma.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of DNA Copy Number Aberrations in ABC Transporter Family Genes on the Survival of Patients with Primary Operatable Non-Small Cell Lung Cancer.","authors":"Matvey Mikhailovich Tsyganov, Marina Konstantinovna Ibragimova, Evgeny Olegovich Rodionov, Anastavia Alekseevna Frolova, Irina Aleksandrovna Tsydenova, Elizaveta Andreevna Lutzkaya, Sergey Viktorovich Miller","doi":"10.2174/0115680096336801241005173638","DOIUrl":"https://doi.org/10.2174/0115680096336801241005173638","url":null,"abstract":"<p><strong>Purpose: </strong>Previous research has shown, that ABC transporters gene expression level can predict the efficacy of therapy. However, other mechanisms of gene activity are rarely considered, especially in non-small cell lung cancer (NSCLC). Thus, the purpose of the work was to assess chromosomal aberrations of all 49 ABC transporters genes and the expression levels of some ABC genes, as well as their correlation with survival.</p><p><strong>Materials and methods: </strong>The surgical material of 104 patients with NSCLC was used in this study. Treatment included surgery and 3 courses of adjuvant chemotherapy with \"platinum doublets\". DNA and RNA were isolated from the samples, followed by microarray analysis to assess the expression and chromosomal aberrations (deletions and amplifications) of ABC genes.</p><p><strong>Results: </strong>Metastatic-free survival (MFS) was higher with ABCC1, ABCC2, and ABCG1 hypoexpression at a statistically significant level (p=0.01). The presence of deletion in ABCB1 correlates with 100% MFS (p=0.001). The survival rates with ABCG1 amplification are not higher than 45% (p<0.0001). ABCA11 deletion is associated with a low MFS rate (38%) versus 91% with normal copy number (p=0.006). ABCB9 analysis showed opposite results, with survival rates of 55% and 91% in the presence of amplification and normal copy number, respectively (p=0.006). ABCC subfamily genes showed a similar result in the presence of amplification, where ABCC3 and ABCC10 account for 64% and 60% survival, respectively (p=0.005, p=0.01).</p><p><strong>Conclusion: </strong>Thus, not only expression but also chromosomal aberrations were found to be associated with patient survival. These findings could be a potential marker of metastatic-free survival.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}